The global GLP-1 agonists weight loss drugs market size was estimated at USD 13.84 billion in 2024 and is projected to reach USD 48.84 billion by 2030, registering a CAGR of 18.54% from 2025 to 2030. Market expansion is being propelled by the growing global burden of obesity, heightened health consciousness, and the proven clinical efficacy of leading therapies such as semaglutide...